BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 24, 2007
 |  BioCentury  |  Strategy

Regeneron's suite deal

Back to the Future

Regeneron's suite deal

Having done a pair of non-exclusive deals for its VelocImmune antibody technology, Regeneron Pharmaceuticals Inc. decided there was a better way to monetize the platform and agreed to give sanofi-aventis Group options to all future therapeutic antibodies the biotech's VelociSuite produces. The partners hope to take two to three antibodies into the clinic each year over five years, which Regeneron will co-develop and have an option to co-promote in the U.S.

VelociSuite includes a pair of gene functionalization technologies - VelociGene and VelociMouse - that generate custom genetic alterations in murine stem cells and validate these potential targets by expressing them in a mouse model for a given disease. The company can then use VelocImmune to create human MAbs against the target (see BioCentury, Feb. 12).

The company signed a pair of non-exclusive deals for...

Read the full 700 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >